Clinical trials
Chemoradiation clinical trials
Below are recruiting chemoradiation clinical trials, each written for real people, not researchers. We’re tracking 95 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06414902RecruitingPhase 1
PET scan to see if chemoradiation is working for esophageal cancer
This trial uses a special PET/CT scan to see how well your esophageal cancer responds to chemotherapy and radiation. It helps doctors find out if the treatment is working early on.
Houston, TexasAges 18 years+ - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Jonesboro, ArkansasAges 18 years+ - NCT06191133RecruitingPhase 1
Fenofibrate for cervical pre-cancer and cancer
This study tests whether a cholesterol-lowering drug called fenofibrate can help people with cervical pre-cancer or cancer. You take the drug before your scheduled surgery or chemoradiation, and doctors check if it reduces abnormal tissue or enhances treatment.
Cleveland, OhioAges 18 years+ - NCT06080061Recruiting
Personalized accelerated chemoradiation for lung cancer
This trial tests a personalized, faster course of radiation combined with chemotherapy for lung cancer. It aims to improve treatment effectiveness while reducing side effects by tailoring the radiation plan to each patient.
Palo Alto, CaliforniaAges 18 years+ - NCT05894083RecruitingPhase 2
PET-Scan Tailored De-escalation for p16+ throat cancer
This trial tests a treatment plan that may lower (de-escalate) therapy intensity for certain p16+ or HPV-positive throat cancers. It uses PET scan results and tumor features to try to keep cancer control while reducing side effects.
Ann Arbor, MichiganAges 18 years+ - NCT05819892RecruitingPhase 1
Dostarlimab with chemo and radiation for advanced womb cancer
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
Houston, TexasAges 18 years+ - NCT05696782RecruitingPhase 2
Durvalumab after chemoradiation for stage III lung cancer
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
Charlotte, North CarolinaAges 18 years+ - NCT05526924RecruitingPhase 1
Phase 1 trial tests re-radiation plus immunotherapy and a cancer pill
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
Chicago, IllinoisAges 18 years+ - NCT05544136RecruitingPhase 2
Study of lower radiation and chemo for head and neck cancer
This study tests whether giving lower doses of radiation and chemotherapy is safe and effective for people with certain head and neck cancers. It aims to reduce side effects while keeping the treatment successful.
Basking Ridge, New JerseyAges 18 years+ - NCT05307939RecruitingPhase 2
Using tumor DNA tests to time treatment for HPV throat cancer
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
Miami, FloridaAges 18 years+ - NCT05212272Recruiting
MRI plus cognitive testing during glioma chemoradiation
This study uses MRI scans and related brain/cognitive testing while you receive standard chemotherapy and radiation for a high-grade brain tumor. It aims to see how MRI measures and brain testing may relate to your treatment response or brain function.
Winston-Salem, North CarolinaAges 18 years+ - NCT05136846RecruitingPhase 1
Papaverine with chemoradiation for stage II–III lung cancer
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT05010109Recruiting
Testing heart safety and fitness during lung cancer chemoradiation
This study looks at how lung cancer treatment affects the heart and whether a “walking test” and blood tests can track heart fitness and injury. It may help by improving how cancer therapy is planned and monitored for heart safety.
Houston, TexasAges 18 years+ - NCT05027633RecruitingPhase 2
Immunotherapy plus chemo and radiation for nasal cancer
This Phase 2 study tests a treatment plan that combines immunotherapy with chemotherapy and chemoradiation for advanced squamous cell cancer in the nasal cavity or sinuses. It aims to improve cancer control in people who are newly diagnosed and have not had prior treatment for this cancer.
Houston, TexasAges 18 years+ - NCT04682158RecruitingPhase 2
Propranolol added to standard chemoradiation for esophageal cancer
This trial studies whether adding propranolol (a common blood-pressure/heart medication) to standard chemotherapy and radiation can improve outcomes for people with esophageal adenocarcinoma. You would start propranolol around the time of treatment, with careful heart monitoring and study follow-up.
Buffalo, New YorkAges 18 years+ - NCT04892953RecruitingPhase 2
Durvalumab plus focused radiation for progressing stage III lung cancer
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
Houston, TexasAges 18 years+ - NCT03322995RecruitingPhase 2
Neoadjuvant chemo study for resectable pancreatic cancer
This Phase 2 trial tests a chemotherapy plan given before surgery (called “neoadjuvant” treatment) for people with pancreatic adenocarcinoma that looks resectable or borderline resectable on scans. The goal is to see how well this adaptive chemotherapy approach works and whether it can improve outcomes before an operation.
Milwaukee, WisconsinAges 18 years+ - NCT04852328RecruitingPhase 2
Testing CUE-101 schedules before treatment for HPV16 throat cancer
This Phase 2 trial studies different timing “schedules” of CUE-101 given before surgery or before chemoradiation for HPV16-positive oropharyngeal throat cancer. The goal is to see if CUE-101 can help the body respond better and potentially improve outcomes.
St Louis, MissouriAges 18 years+ - NCT04821843RecruitingPhase 3
Study before-surgery treatments for esophageal cancer
This Phase 3 trial compares different “treatments before surgery” for people with esophageal (or esophagus-to-stomach) cancer. It aims to see which approach works better to control the cancer and improve outcomes after surgery.
BeijingAges 18 years+ - NCT04821778RecruitingPhase 3
Testing chemoradiotherapy for esophageal and stomach junction cancer
This Phase 3 study tests a cancer treatment plan that combines chemotherapy and radiation for people with esophageal or esophagus-stomach junction cancer. It aims to see whether this approach works better than standard care for cancers at stages I to IVA.
Anyang, HenanAges 18 years+ - NCT03853915Recruiting
PET scan and HPV testing during chemoradiation for cervical cancer
This study looks at whether a PET scan (FDG-PET/CT) and blood HPV testing can help track cervical cancer responses during and after standard chemo-radiation. It may help doctors better understand who is responding and who may need different care.
Toronto, OntarioAges 18 years+ - NCT03516708RecruitingPhase 1/Phase 2
Epacadostat with pre-op radiation for locally advanced rectal cancer
This trial studies whether adding epacadostat (a cancer drug) to standard pre-operative chemoradiation can improve outcomes for people with locally advanced rectal cancer. It’s designed to see if the added treatment is safe and potentially more effective before surgery.
Orange, CaliforniaAges 18 years+ - NCT02421718Recruiting
Follow-up program for lung cancer and related conditions after radiation
This trial studies a standard follow-up plan to help you stay on track after radiation treatment for lung cancers or certain related conditions. It may help your care team monitor symptoms and outcomes in a consistent way.
Groningen, Provincie GroningenAges 18 years+
Hear when a new Chemoradiation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chemoradiation?
- Yes. Clin2 currently lists 95 recruiting chemoradiation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chemoradiation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chemoradiation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.